Sotrovimab Expanded Access Treatment Protocol

Vir Biotechnology, Inc.1 个研究点分布在 1 个国家开始时间: 2022年2月11日最近更新: 2022年11月10日

适应症

试验速览

阶段: 不适用
状态: No Longer Available
发起方: Vir Biotechnology, Inc.
试验地点: 1

研究概览入排标准研究者研究点记录与标识符相似试验

研究概览

简要总结

An expanded access program for sotrovimab administered intravenously to participants with COVID-19 illness who meet current authorized/approved criteria for use of sotrovimab.

研究设计

研究类型: Expanded Access

入排标准

年龄范围: 12 Years 至 —（Child, Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•In the opinion of the investigator, meets the current Emergency Use Authorization (EUA) eligibility criteria for sotrovimab
•patients currently hospitalized for a non-COVID-19 illness who acquire COVID-19 (nosocomial infection) and otherwise meets all the current EUA eligibility criteria

排除标准

•Hospitalized due to COVID-19 (excludes nosocomial infection)
•Require oxygen therapy due to COVID-19, OR who require an increase in baseline oxygen flow rate due to COVID-19

研究者

发起方

Vir Biotechnology, Inc.

申办方类型

Industry

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

No Longer Available

不适用

CAP-1002 in Severe COVID-19 DiseaseCOVID-19

NCT04338347Capricor Inc.

已完成

3 期

An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).Advanced Renal Cell Carcinoma

NCT01076010AVEO Pharmaceuticals, Inc.277

No Longer Available

不适用

Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)Severe Acute Respiratory Syndrome Coronavirus 2

NCT04360486U.S. Army Medical Research and Development Command

已完成

2 期

A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised IndividualsSARS CoV 2 Infection

NCT05210101Sophia Koo, M.D.93

Approved For Marketing

不适用

Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye DiseaseGraves' OrbitopathyThyroid Eye Disease

NCT04040894Amgen